Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase I trial is studying the side effects of dasatinib in treating patients
with chronic myelogenous leukemia or acute lymphoblastic leukemia.